Literature DB >> 11914243

High-density lipoprotein restores endothelial function in hypercholesterolemic men.

Lukas E Spieker1, Isabella Sudano, David Hürlimann, Peter G Lerch, Markus G Lang, Christian Binggeli, Roberto Corti, Frank Ruschitzka, Thomas F Lüscher, Georg Noll.   

Abstract

BACKGROUND: Hypercholesterolemia is a risk factor for atherosclerosis-causing endothelial dysfunction, an early event in the disease process. In contrast, high-density lipoprotein (HDL) cholesterol inversely correlates with morbidity and mortality representing a protective effect. Therefore, we investigated the effects of reconstituted HDL on endothelial function in hypercholesterolemic men. METHODS AND
RESULTS: Endothelium-dependent and -independent vasodilation to intraarterial acetylcholine and sodium nitroprusside (SNP), respectively, was measured by forearm venous occlusion plethysmography in healthy normo- and hypercholesterolemic men. In hypercholesterolemics, the effects of reconstituted HDL (rHDL; 80 mg/kg IV over 4 hours) on acetylcholine- and SNP-induced changes in forearm blood flow were assessed in the presence or absence of the nitric oxide (NO) synthase inhibitor L-NMMA. Hypercholesterolemics showed reduced vasodilation to acetylcholine but not to SNP compared with normocholesterolemics (P<0.0001). rHDL infusion increased plasma HDL cholesterol from 1.3+/-0.1 to 2.2+/-0.1 mmol/L (P<0.0001, n=18) and significantly enhanced the acetylcholine-induced increase in forearm blood flow without affecting that induced by SNP. rHDL infusion also improved flow-mediated dilation of the brachial artery (to 4.5+/-0.9% from 2.7+/-0.6%, P=0.02). NO synthase inhibition prevented the improvement in acetylcholine-induced vasodilation while leaving the response to SNP unchanged. Albumin infusion in an equivalent protein dose had no effect on vasomotion or lipid levels.
CONCLUSIONS: In hypercholesterolemic patients, intravenous rHDL infusion rapidly normalizes endothelium-dependent vasodilation by increasing NO bioavailability. This may in part explain the protective effect of HDL from coronary heart disease and illustrates the potential therapeutic benefit of increasing HDL in patients at risk from atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11914243     DOI: 10.1161/01.cir.0000013424.28206.8f

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  93 in total

Review 1.  Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.

Authors:  Martin Hersberger; Arnold von Eckardstein
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  HDL action on the vascular wall: is the answer NO?

Authors:  Philip W Shaul; Chieko Mineo
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

3.  Cholesteryl ester transfer protein inhibition and endothelial function: enough with the surrogates.

Authors:  Prediman K Shah
Journal:  Eur Heart J       Date:  2012-02-20       Impact factor: 29.983

Review 4.  The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

Authors:  Menno Vergeer; Adriaan G Holleboom; John J P Kastelein; Jan Albert Kuivenhoven
Journal:  J Lipid Res       Date:  2010-04-06       Impact factor: 5.922

Review 5.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.

Authors:  Rui Kuai; Dan Li; Y Eugene Chen; James J Moon; Anna Schwendeman
Journal:  ACS Nano       Date:  2016-02-25       Impact factor: 15.881

6.  The role of 'paraoxonase-1 activity' as an antioxidant in coronary artery diseases.

Authors:  Maharudra Shekhanawar; Sarala M Shekhanawar; D Krisnaswamy; V Indumati; D Satishkumar; V Vijay; T Rajeshwari; M Amareshwar
Journal:  J Clin Diagn Res       Date:  2013-07-01

Review 7.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease.

Authors:  Philip J Barter; Rajesh Puranik; Kerry-Anne Rye
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

Review 9.  Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.

Authors:  Emil M deGoma; Rolando L deGoma; Daniel J Rader
Journal:  J Am Coll Cardiol       Date:  2008-06-10       Impact factor: 24.094

10.  Nanomedicines for Endothelial Disorders.

Authors:  Bomy Lee Chung; Michael J Toth; Nazila Kamaly; Yoshitaka J Sei; Jacob Becraft; Willem J M Mulder; Zahi A Fayad; Omid C Farokhzad; YongTae Kim; Robert Langer
Journal:  Nano Today       Date:  2015-12-01       Impact factor: 20.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.